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MethodAbstract
RNA interference (RNAi) high-throughput screening (HTS) enables massive parallel gene silencing and is increasingly being used to reveal
novel connections between genes and disease-relevant phenotypes. The application of genome-scale RNAi relies on the development of high-
quality RNAi HTS assays. To obtain high-quality HTS assays, there is a strong need for an easily interpretable and theoretically based quality
control (QC) metric. Signal-to-noise ratio (S/N), signal-to-background ratio (S/B), and Z-factor have been adopted as QC metrics in HTS
assays. In this paper, I proposed a pair of new parameters, strictly standardized mean difference (SSMD) and coefficient of variability in
difference (CVD), as QC metrics in RNAi HTS assays. Compared to S/B and S/N, SSMD and CVD capture the variabilities in both compared
populations. Compared to Z-factor, SSMD and CVD have a clear probability interpretation and a solid statistical basis. Accordingly, the cutoff
criteria of using SSMD or CVD as a QC metric in HTS assays are fully theoretically based. In addition, I discuss the relationship between the
SSMD-based criterion and the popular Z-factor-based criterion and elucidate why p-value from t-test of testing mean difference fails to serve
as a QC metric.
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for gene silencing [1,2], has made its way as a widely used
method in molecular biology in both academics and industry.
Academic researchers have used RNAi to elucidate gene
functions through studying a loss-of-function phenotype.
Pharmaceutical and biotech companies have set up libraries
for large-scale screens employing thousands of short-interfering
RNA- (siRNA) or short hairpin RNA- (shRNA) encoding
vectors to identify new factors involved in the molecular
pathways of diseases [3]. RNAi may lead to advances not only
in drug target identifcation and validation but also in the
development of a potential whole new class of RNAi-based
therapeutic agents [4]. The first clinical trials based on RNAi
were initiated to treat patients with age-related macular
degeneration [5]. RNAi has even been seen as the third class⁎ Fax: +1 215 993 1835.
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doi:10.1016/j.ygeno.2006.12.014of drug targets after small molecules and proteins [6]. Based on
siRNA or shRNA libraries, RNAi high-throughput screening
(HTS) enables massive parallel gene silencing to reveal the
extent to which interference with the expression of specific
genes alters the cell phenotype, and it is increasingly being used
to reveal novel connections between genes and disease-relevant
phenotypes [7–10].
Statistical methods for small-molecule HTS data have been
described [11–15]. Zhang et al. [16,17] explored statistical
methods for hit selection in RNAi HTS experiments. The
application of genome-scale RNAi relies on the development of
high-quality RNAi HTS assays. However, despite a strong need
for a theoretically based and easily interpretable quality control
(QC) metric in RNAi HTS assays, such a QCmetric has yet to be
developed. An important QC characteristic in an HTS assay is
how much the positive controls, tested compounds, and negative
controls differ from one another in the assay. This QC
characteristic can be evaluated using the comparison of two
well types in HTS assays.
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and Z-factor have been adopted to evaluate the quality of HTS
assays through the comparison of two investigated types of
wells. However, S/B does not take into account any informa-
tion on variability; and S/N can capture the variability only in
one group and hence cannot assess the quality of assay when
the two groups have different variabilities. Zhang et al. [11]
proposed a screening window coefficient called “Z-factor.” The
advantage of Z-factor over S/N and S/B is that it takes into
account the variabilities in both compared groups. As a result,
Z-factor has been broadly used as a QC metric in HTS
assays (cf. [7,11,18–21]). However, its probability basis has
not been explored and its statistical properties have not been
investigated.
In this paper, I propose a pair of novel parameters, strictly
standardized mean difference (SSMD) and its reciprocal,
coefficient of variation of difference (CVD), for measuring
the magnitude of difference between two populations, and I
investigate their capacity as QC metrics in RNAi HTS assays.
Like Z-factor, SSMD and CVD capture the variabilities in both
groups; and they are simple statistical parameters. But unlike
the Z-factor, this pair of parameters has a clear probability
intrepretation and a solid statistical basis.Methods
Suppose two populations P1 and P2 with random value have distributions
of F1 and F2, respectively. The first population has mean μ1 and variance σ1
2
and the second population has mean μ2 and variance σ2
2. The covariance
between these two populations is σ12. Further suppose we have one sample
of size n1, namely X11, X12,… , X1n1, being independently identically
distributed from the first population and another independent sample of
size n2, namely X21, X22,… , X2n2, being independently identically distributed
from the second population. X¯1 and s1 are respectively the sample mean and
the sample standard deviation (SD) in the first sample; X¯2 and s2 are
respectively the sample mean and the SD in the second sample.
Signal-to-noise ratio and Z-factor
Historically, S/N and S/B are two measures that have been used loosely in
small-molecule HTS assays. Their definitions are
S=N ¼ l1  l2
r2
and S=B ¼ l1
l2
:
The criticism for S/B (and the mean difference μ1−μ2) is that it does not contain
any information regarding data variability. S/N does take into account the
variability, but only in a single population. It does not take into account the
variability in the other population.
Z-factor was proposed to measure the separation between “tested
compound” wells and “negative control” wells or between “positive control”
wells and “negative control” wells. Let Zf denote Z-factor. Z-factor is defined
as [11]
Zf ¼ 1 3ðr1 þ r2Þjl1  l2j
: ð1Þ
Zhang et al. [11] further use “Z-factor” to refer to the parameter between tested
compound wells and negative control wells and “Z′-factor” to refer to the
parameter between positive control wells and negative control wells. For
convenience, we will use Z-factor to refer to either of them depending on thecompared groups in this paper. As the authors pointed out, the Z-factor that
they used is a plug-in formula as follows:
Zf ¼ 1 3ðs1 þ s2ÞjX¯1  X¯2j
: ð2Þ
They used sample mean directly in the position of population mean and sample
SD in the position of population SD in the formula for Z-factor. The point
estimate or interval estimation of Z-factor has not been investigated from a
solid statistical basis. The meaning of Z-factor has not been explored from a
probability perspective. Below, I propose a pair of new parameters with a solid
probability and statistics basis that can take into account the variabilities in both
groups.
A pair of new parameters
Let D denote the difference between populations P1 and P2, namely
D=P1−P2. The mean μd and variance σd2 of D are μd=μ1−μ2 and σd2=
σ1
2+σ2
2−2σ12, respectively. The ratio of mean to SD of the difference D is
defined as strictly standardized mean difference. Let β denote SSMD. Then
b ¼ ld
rd
¼ l1  l2ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
r21 þ r22  2r12
p : ð3Þ
If the two populations are independent, σ12=0 and σd
2=σ1
2 +σ2
2. Then
b ¼ l1  l2ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
r21 þ r22
p : ð4Þ
The larger the absolute value of SSMD between two populations, the greater
the differentiation between the two populations. The term “standardized mean
difference” [22] has been used as a type of effect size, referring to the mean
difference standardized to the SD of the control group or the average SD under
the assumption of equal variance. For example, S/N is such a type of standardized
mean difference. Here, the mean of the random variable representing the
difference is strictly standardized to SD of the random variable itself; thus we
have the name “strictly standardized mean difference” for this parameter.
The coeffcient of variation in difference is defined as the coeffcient of
variation of D. Let ω denote CVD. Then
x ¼ rd
ld
¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
r21 þ r22  2r12
p
l1  l2
: ð5Þ
If the two populations are independent,
x ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
r21 þ r22
p
l1  l2
: ð6Þ
As in the original meaning of coefficient of variability for a random variable,
CVD represents the relative SD of the difference with respect to mean of the
difference. The larger the absolute value of CVD between two populations, the
less the differentiation between the two populations. Clearly, CVD is the
reciprocal of SSMD. However, CVD=∞ when μ1=μ2, which may make CVD
less favorable than SSMD in some situations.
Let Z denote the standardized difference (namely Z ¼ D ld
rd
) and FZ (·) be
the cumulative distribution function of Z. Then
Pr D>0ð Þ¼Pr D ld
rd
>
0 ld
rd
 
¼Pr Z>bð Þ¼1FZ bð Þ:
Thus, the probability that the difference D is positive is a function of β. For
convenience, let us call this probability “positive difference probability” and use
d+-probability to denote it. That is, d+-probability=Pr(D>0). When the
difference D is symmetrically distributed, d+-probability=Pr(Z>−β) =Pr
(Z<β). When D is normally distributed, the relationship between SSMD and
554 X.D. Zhang / Genomics 89 (2007) 552–561d+-probability is as simple as d+-probability=Φ(β) where Φ(·) denotes the
cumulative distribution function of the standard normal distribution N(0,1).
Hence, the value of SSMD reflects the probability of the difference being
greater than 0. The larger the value of SSMD, the greater the probability of the
difference being greater than 0. In other words, SSMD has a clear meaning
indicated by the d+-probability.
Statistical estimation and inference of SSMD and CVD
In this paper, we focus on the estimation and inference under the condition of
independence between two populations, namely based on the definitions of Eqs.
(4) and (6). We can obtain maximum likelihood estimates (MLEs) of SSMD and
CVD and their asymptotic distributions using the Delta method and the
asymptotic normality of MLE. The results are summarized in Proposition 1,
which is presented and proved in the Appendix.
Based on Proposition 1, we obtain the MLE point estimate β̂ as follows:
b ̂ ¼ X
¯
1  X¯2ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
n1  1
n1
s21 þ
n2  1
n2
s22
r ; ð7Þ
Let Za=2 ¼ U 1 a2
 
. Using the asymptotic variance σβˆ
2
and the invariance
property of MLE, the 1-α confidence interval of β is approximately
X¯1  X¯2ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
n1  1
n1
s21 þ
n2  1
n2
s22
r FZa
2
r̂b ̂ ; ð8Þ
where
r ̂b ̂
2 ¼
n1  1
n21
s21 þ
n2  1
n22
s22
n1  1
n1
s21 þ
n2  1
n2
s22
þ
ðn1  1Þ2
n31
s41 þ
ðn2  1Þ2
n32
s42
2
n1  1
n1
s21 þ
n2  1
n2
s22
 3 X¯1  X¯2 2:
Similarly, we can obtain the MLE point estimate and confidence interval of ω.
See the Appendix for more details.
So far, the point and interval estimations have been derived using MLE.
Other point estimates for both SSMD and CVD can also be useful. For example,
considering that X¯1, X¯2, s1
2, and s2
2 are unbiased estimates, respectively, for μ1,
μ2, σ1
2, and σ2
2, a method-of-moment (MM) estimate for SSMD or CVD may be
obtained as follows:
b ̂MM ¼
X¯1  X¯2ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
s21 þ s22
p and x̂MM ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
s21 þ s22
p
X¯1  X¯2
: ð9Þ
When the distributions of the two populations have non-normality,
skewness, and outliers, the robust point estimates for SSMD and CVD may
respectively be
b ̂robust ¼
X˜1  X˜2ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
s˜21 þ s˜22
p and x̂robust ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
s˜21 þ s˜22
p
X˜1  X˜2
; ð10Þ
where X˜ i and s˜i (i=1, 2) are respectively the median and median absolute
deviation (MAD) of the sample from the ith population. To match SD with
MAD in a sample from a normal distribution, we may use the rescaled
MAD, namely, si=1.4826 median (|Xij–X˜i|) (i=1, 2; j=1,… , ni). It may be
worthwhile to note that the SSMD and CVD robust estimates are approxima-
tions, which may not estimate exactly the same underlying parameter as the
nonrobust measures.
Comparison of parameters for QC in RNAi HTS assays
We compare S/B, S/N, Z-factor, CVD, and SSMD as population parameters
for quality control in RNAi HTS assays on the condition of normal distributionswith known means and standard deviations in a positive control and a negative
control. Fig. 1 displays some typical population distributions of positive and
negative controls appearing in RNAi HTS assays. The clear differentiation
between these two controls indicates good quality of an HTS plate.
S/B does not contain any information regarding data variability. S/N is based
on the assumption that the two compared populations compared have the same
variability. If the variabilities in the two populations aredifferent, both S/B and
S/N will produce misleading results. For example, S/B=0.71 and S/N=6.67 in
Cases A, C, and D of Fig. 1. However, we can clearly see that the separation
between the positive and the negative controls in these three cases are very
different. Furthermore, the cutoff criterion of using S/N to evaluate QC is hardly
clear. For example, we see that the S/N in Cases A and D are all high and may
think about a cutoff of 6 for S/N. Even if we used this big cutoff value, we would
still conclude that there is good differentiation between the positive and the
negative controls in Case C, which has an S/N value bigger than 6. This is
clearly a misleading result as seen in Fig. 1.
The Z-factor is the ratio of the separation band, |μ1–μ2|–(3σ1+3σ2), to
the signal dynamic range, |μ1–μ2|, of an assay. It is clear that Z-factor
captures the mean difference and the variabilities in both compared
populations. As a result, Z-factor works better than S/B and S/N as a QC
metric and has thus been broadly used in HTS assays (cf. [7,11,18–21]). For the
use of Z-factor as a QC metric in small-molecule HTS assays, Zhang et al. [11]
proposed the following cutoff criterion: Z-factor =1 for “ideal assay,” 1>
Z-factor ≥0.5 for “excellent assay,” 0.5>Z-factor >0 for “doable assay,”
Z-factor=0 for “yes/no type assay,” and Z-factor <0 for “screening essentially
impossible.” Using this Z-factor-based criterion, Cases A, D, and F are
classified as “doable assays” meaning “separation band is small”; Cases B, C,
and E are classified as “screening essentially impossible.” However, the
probability meaning of this Z-factor-based criterion is still unclear.
The major part of Z-factor,
r1 þ r2
jl1  l2j
, looks similar to CVD,
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
r21 þ r22
p
jl1  l2j
.
Like Z-factor, CVD and SSMD measure the magnitude of difference and
capture the variabilites in both populations. But unlike the Z-factor, SSMD and
CVD and their cutoff criteria are easily interpretable in probability. For
example, SSMD ≥3 indicates that the size of the mean difference is at least
three times that of the SD of the difference between two populations. As a
probability intrepretation, SSMD ≥3 indicates that the probability that a value
from the first population is greater that a value from the second population is
greater than Φ(3)=0.99865 when the difference is normally distributed, and is
greater than 0.95 when the difference has a distribution with unimode and
finite variance. Thus, we may set up the following simple criterion for quality
control: in the situation in which the positive control has value greater than the
negative control, a plate passes in QC if it has SSMD ≥3 and fails in QC if it
has SSMD <3; in the situation in which the positive control has value less than
the negative control, a plate passes in QC if it has SSMD ≤ −3 and fails in QC
if it has SSMD > −3. Both the |SSMD| ≥3 criterion and the mean±3×SD
method originate from the well-known three sigma rule.
Using the SSMD-based criterion, the SSMD values are above 3 in Cases A,
D, E, and F and are less than 3 in Cases B and C, which suggests that there is
good differentiation between positive and negative controls in Cases A, D, E,
and F but poor differentiation in Cases B and C. This result is sensible as
displayed in Fig. 1. The d+-probabilities (namely the probabilities that a value
from positive control is greater than a value from the negative control) in Cases
A, D, E, and F are respectively 2.6×10−6, 3×10−10, 3.7×10−5, and 5.7×10−5,
all very small, while the probabilities in Cases B and C are respectively 0.123
and 0.081, both fairly high. This offers meaningful information on the
magnitude of difference between positive and negative control in each plate
from a probability perspective.
The probability meaning of SSMD also provides a basis for a pro-
bability interpretation to Z-factor-based criterion. Using the inequality ofﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
r21 þ r22
p
< r1 þ r2 whenσ1>0 andσ2>0, we can get jSSMDj > 31 Z-factor.
Therefore, given a value a (not greater than 1), if Z factor> a then
jSSMDj > 3
1 a; however, if jSSMDj >
3
1 a, we cannot ensure that Z-
factor>a. For example, if Z-factor>0 (or 0.5) then |SSMD| >3 (or 6). However,
if |SSMD| >3 (or 6), we cannot ensure that Z-factor>0 (or 0.5). An example of
|SSMD| >3 but Z-factor<0 is displayed in Fig. 1E. Thus, Z-factor>0 (or 0.5) is a
Fig. 1. (A–F) Population distributions of a positive control and a negative control (represented by the right and left curves, respectively) in six typical cases appearing in
RNAiHTS assays. In each, the x axis and y axis denote intensity (in−log2 scale) and distribution density, respectively. The values ofmean (μ), standard deviation (σ), and
QC parameters in the six plates are (A) μ1 = −10, σ1 = 0.64, μ2 = −14, σ2 = 0.60, β = 4.56, Zf = 0.07, S/N = 6.67, S/B = 0.71; (B) μ1= −11, σ1 = 1.20, μ2= −13, σ2 =
1.24, β = 1.16, Zf= −2.66, S/N = 1.61, S/B = 0.85; (C) μ1= −10, σ1 = 2.80, μ2= −14, σ2 = 0.60, β = 1.40, Zf = −1.55, S/N = 6.67, S/B = 0.71; (D) μ1=
−10, σ1 = 0.24, μ2= −14, σ2 = 0.60, β = 6.19, Zf = 0.37, S/N = 6.67, S/B = 0.71; (E) μ1= −12.65, σ1 = 0.146, μ2= −13.44, σ2 = 0.136, β = 3.96, Zf =
−0.07, S/N = 5.8, S/B = 0.94; (F) μ1= −12.65, σ1 = 0.198, μ2 = −13.44, σ2 = 0.052, β = 3.86, Zf = 0.05, S/N = 15.2, S/B = 0.94.
555X.D. Zhang / Genomics 89 (2007) 552–561subset of |SSMD| >3 (or 6). In other words, the criterion of Z-factor>0 is more
conservative than the criterion of |SSMD| >3.
In reality, we ususally do not know the population values of mean and
variance in the control groups and thus we do not know the population values of
the above QC parameters. We must make statistical estimations and inferences
based on random samples from the control groups. As presented previously,
SSMD and CVD estimates have clear statistical properties, while the properties
of the Z-factor estimate seem difficult to determine.
Comparison of SSMD and classical t-statistic
It is well known that t-test has widely been used for the comparison of two
populations. The t-statistic for testing no mean difference under the situation of
unequal variance is t ¼ X
¯
1  X¯2ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
s21
n1
þ s22n2
q , which looks similar to the MLE estimate of
SSMD, βˆ in Eq. (7), and theMM estimate of SSMD, βˆMM in Eq. (9). The difference
is in the denominators. As a result, the classical t-statistic is a function of both
sample size and magnitude of difference. In general, larger sample size leads to
larger absolute t-value and smaller p-value. In fact, as the total sample size
N→∞, t-value goes to ∞ or –∞ and p-value goes to 0. By contrast, from
Proposition 1, as sample size increases, the SSMD estimate goes to the trueSSMD value, β0, in probability. β0 is usually a limited number. Consequently,
as N→∞, the SSMD estimate will not go to ∞ or −∞. Sample size can impact
only how accurately and precisely SSMD estimate can represent SSMD true
value, which is reflected in the confidence interval of β as shown in Eq. (8).
Otherwise, sample size has no impact on SSMD. Thus, we can still maintain
the benefit of increasing sample size in an assay: increasing the accuracy and
precision of the SSMD estimation by making the variance of βˆ smaller and
the confidence interval of β narrower.
Let us compare the performance of SSMD and the t-statistic (for testing
H0: μ1≤μ2) for QC in RNAi HTS assays. Suppose we observe four plates
(Plates A1, B1, B2, and C1) with Plate A1 from Case A of Fig. 1, Plates B1 and
B2 from Case B, and Plate C1 from Case C. The sample means, SDs, and
sample sizes of the four plates are listed in the first column of Table 1. Since
Plates B1 and B2 are from Case B, the value of a good QC metric should be
approximately the same in these two plates. However, as shown in Table 1,
from Plates B1 to B2, t-value is doubled and p-value changes from 0.034 to
3.5×10−5, whereas βˆ changes only slightly from 1.338 to 1.197. This is one
piece of evidence that classic t-statistic for testing no mean difference cannot
work effectively as a QC metric in RNAi HTS assays, while SSMD can. In
addition, if we used the p-values from t-tests to evaluate the quality of
RNAi HTS assays, we might have concluded that Plates B2 nd C1 had
better differentiation between positive and negative controls (and thus had
Table 1
SSMD and classical t-test for comparing difference between groups
Sample mean, SD, and sample size β̂ t-value p-value
A1 X¯ 1=−10, s1=0.64, n1=4 5.265 9.119 1.3×10−4
X¯ 2=−14, s2=0.60, n2=4
B1 X¯ 1=−11, s1=1.20, n1=4 1.338 2.318 0.034
X¯ 2=−13, s2=1.24, n2=4
B2 X¯ 1=−11, s1=1.20, n1=16 1.197 4.636 3.5×10−5
X¯ 2=−13, s2=1.24, n2=16
C1 X¯ 1=−10, s1=2.8, n1=16 1.443 5.587 2×10−5
X¯ 2=−14, s2=0.6, n2=16
556 X.D. Zhang / Genomics 89 (2007) 552–561better quality) than Plate A1 because the p-values in Plates B2 and C1 are
smaller than in Plate A1. This is clearly a misleading judgement as Plate A1 is
from Case A, which clearly has much better differentiation between positive
and negative controls than Cases B and C.Results
A good QC metric should work in a variety of
experiments. Thus in this paper we concentrate on platesFig. 2. Data from positive and negative controls (shown at the bottom) and the estimat
HTS experiments, A, B, and C. At the bottom, a red (or green) point represents the m
two orange dashed lines represent the cutoffs of β̂=3 and Z ̂ f=0, respectively. A bla
blue) cross represents the estimated (or robust) value of Z-factor in a plate.extracted from different RNAi HTS experiments, which may
have different data ranges and different numbers of positive
and negative control wells, so that we can see the impact of
sample size and data range on the QC metrics. The data are
extracted from several experiments on diseases such as
infectious diseases and cancers, including a hepatitis C virus
RNAi HTS experiment described in Zuck et al. [7] and Zhang
et al. [17].
The bottom of Fig. 2 shows the data from plates 1–11,
12–15 and 16–18 of experiments A, B, and C, respectively.
The data have the following notable features. The data range
(between −3.5 and 0.5) in Experiment A was different from
those (between −18 ane −8) in Experiments B and C. The
numbers of control wells at each plate differed in each of
the three experiments: 16 positive control wells and 16
negative control wells in Experiment A, 16 positive control
wells and 8 negative control wells in Experiment B, and 4
positive control wells and 8 negative control wells in
Experiment C. The measured intensities in −log2 scale were
roughly symmetric with a few outliers. There were outliers
in the positive controls in Plates 3, 4, 15, and 16 and in theed values of SSMD and Z-factor (shown at the top) for 18 plates from three RNAi
easured intensity of a positive (or negative) control well in a plate. At the top, the
ck (or blue) dot represents the estimated (or robust) value of SSMD; a black (or
557X.D. Zhang / Genomics 89 (2007) 552–561negative controls in Plates 5 and 12. Even in the plates
without outliers in the same experiment, the data variabil-
ities (indicated by s1) in positive controls sometimes differ
from those (indicated by s2) in negative controls. For
example, s1 (=0.29) nearly doubled s2 (=0.17) in Plate 1,
whereas s1 (=0.11) was nearly the half size of s2 (=0.20) in
Plate 11. There were also cases in which the variabilities in
the two controls were approximately equal, such as
s1 =0.27 and s2 =0.29 in Plate 7 and s1 =0.20 and
s2=0.25 in Plate 8.
Considering the unequal variabilities in the two controls
and different data ranges in different experiments, S/N and S/
B cannot work effectively as QC metrics here. Thus, we
focused on investigating the use of SSMD and Z-factor as QC
metrics. For simplicity, we used the point MLE estimate of
SSMD, βˆ in Eq. (7), and the commonly used plug-in estimate
of Z-factor, Zˆ f in Eq. (2), and we used the simple cutoff
criteria of βˆ>3 for a pass in QC when using SSMD and
Zˆ f>0 when using Z-factor. Considering outliers, we also used
the robust estimate of SSMD in Eq. (10) and a similar robust
estimate of Z-factor as follows:
Z˜ f robust ¼ 1 3ðs˜1 þ s˜2ÞjX˜1  X˜2j
: ð11Þ
The estimated values of SSMD and Z factor are shown
respectively using the black dots and black crosses at the
top of Fig. 2. The robust estimates are shown in blue.
The judgment of QC for the 18 plates are summarized in
Table 2. From Table 2, all the plates that passed in QC by
Z-factor also passed in QC by SSMD. However, three plates
(Plates 6, 7, 13) that did not have outliers passed in QC by
SSMD but not by Z-factor, which demonstrates in practice
that Z-factor>0 is a subset of SSMD>3 as described under
Methods.
Let us first look at Plates 1–15, in each of which there
were 16 positive control wells and at least 8 negative
control wells. From the data shown at the bottom of Fig. 2,
we observed that the positive controls and the negative
controls were not well differentiated from one another in
Plates 1 and 2 and were well differentiated in Plates 6–14.
We also observed outliers in the positive controls of Plates
3, 4, and 15 and in the negative controls of Plates 5 and
12. For the plates without outliers, using SSMD, Plates 1
and 2 failed in QC and Plates 6–11 and 13–14 all passedTable 2
The results of QC evaluation using Z factor and SSMD
Result category Outlier in a plate Plates
Pass in QC by both metrics Without outlier Plates 8, 9, 10,
11, 14, 17, 18
Fail in QC by both metrics Without outlier Plates 1, 2
Fail in QC by both metrics With outlier Plates 3, 4, 16
Pass in QC only by SSMD Without outlier Plates 6, 7, 13
Pass in QC only by SSMD With outlier Plates 5, 12, 15in QC, which matches with the observation of the differen-
tiation in these plates. Using Z-factor in the plates without
outliers, Plates 1, 2, 6, 7, and 13 failed in QC and Plates
8–11 and 14 passed in QC. The judgment by the Z-factor
in Plates 6, 7, and 13 suggest that the Z-factor criterion is
conservative.
Both SSMD and Z-factor indicated that Plates 3 and 4 failed
in QC. If we ignore the outliers, the differentations between
positive and negative controls in Plates 3 and 4 were even
stronger than in Plates 8–10, which is suggested by estimated
robust values of SSMD and Z-factor. This result indicates that
both SSMD and Z-factor are affected by outliers. It is also
notable that Plates 5, 12, and 15 each also had one less extreme
outlier; however, they all passed in QC by SSMD but failed by
Z-factor, which might suggest that SSMD is more robust to
outliers than Z-factor.
The differentiation between the positive control and the
negative control in Plates 8, 9, and 10 appeared to be very
similar although Plate 8 had nearly equal variabilities, Plate 9
had greater variability in the positive control, and Plate 10 had
greater variability in the negative control. The estimated
values SSMD and Z-factor were nearly the same in each of the
three plates (top of Fig. 2), which suggests that both SSMD
and Z-factor worked effectively in the situations of either
equal or unequal variabilities in two groups. However, the
robust estimates in these three plates varied, which reminds us
to be cautious in using robust estimates since the distribution
and variance of robust estimates are difficult to determine.
Robust estimation certainly does not work as well as regular
estimation in the normality situation without outliers, although
it works better when there are outliers and nonsymmetric
distributions.
From the bottom of Fig. 2, it is fairly clear that the
positive control was well differentiated from the negative
control in Plate 17. However, it is not clear whether Plates 16
and 18 really passed or failed in QC although Plate 16 was
classified as “fail” and Plate 18 as “pass” by both SSMD and
Z factor. In Plate 18, the mean difference between the two
controls was not large and the estimated variability in the
positive control was much smaller than in the remaining
plates in Experiments B and C (s1=0.18 in Plate 18 vs
s1=1.05 and 0.39, respectively, in Plates 16 and 17). If we
have one more observation in the positive control that is
reasonably less than the smallest observed value in Plate 18,
the estimated variability may be nearly the same in Plate 17
and it will fail in QC. On the other hand, if we remove the
smallest observed value in Plate 16, then the positive control
will be well differentiated from the negative control.
However, by removing one value, we remove 25% of the
data since there were only four observed values in the
positive control. Therefore, it is not easy to judge the quality
in Experiment C because the number of observed values in
the positive control was too small. By contrast, it is fairly
clear that Plates 12 and 15 should have good quality and
they were judged as “pass in QC” by SSMD even though
there was one extremely low value among the 8 negative
control wells in Plate 12 and one extremely low value among
558 X.D. Zhang / Genomics 89 (2007) 552–561the 16 positive control wells in Plate 15 of Experiment B.
Therefore, this observation suggests that four replicates in a
control are not enough, while eight or more replicates may
be enough for using the QC criterion based on estimated
SSMD.Discussion
The application of genome-scale RNAi relies on the
development of high-quality RNAi HTS assays. To obtain
high-quality HTS assays, there is a strong need for a
generally acceptable QC metric that can be applied to various
HTS assays (including RNAi HTS assays) conducted in
different labs and/or at various times. This metric should have
a solid theoretical basis and clear probability meanings. The
classical t-test for testing no mean difference cannot work
well as a QC metric in RNAi HTS assays as demonstrated
under Methods. The currently available QC parameters, S/B,
S/N, and Z-factor, all have disadvantages. In this paper, a
pair of new parameters, SSMD and CVD, is proposed for
measuring the magnitude of difference between two groups
and is then investigated for evaluating the quality of RNAi
HTS assays.
As investigated under Methods, SSMD and CVD have
clear theoretical advantages over the currently used QC
parameters, S/B, S/N, and Z-factor, as QC parameters in
RNAi HTS assays. Compared to S/B and S/N, SSMD and
CVD capture the variabilities in both compared populations.
Compared to Z factor, SSMD and CVD have clear probability
meanings (represented by d+-probability) and solid statistical
bases. The SSMD-based cutoff criterion has a solid prob-
ability basis, while the Z-factor-based criterion is more or less
empirical. Hence, from a probability and statistics perspective,
the statistical inference of SSMD and CVD is fully
theoretically based. The comparison of SSMD and Z-factor
in data from real RNAi HTS assays targeting different
diseases further suggests that the use of SSMD as a QC
metric in HTS assays leads to more sensible results than using
Z-factor.
The application of SSMD in data from real RNAi HTS
assays with various data ranges, data variabilities, and rep-
licate numbers demonstrates that SSMD is robust to different
data ranges and data variability. In addition, it gives
suggestions on how to use SSMD or CVD as QC metrics in
RNAi HTS assays. Usually, the first question to be faced in
RNAi HTS assays is the determination of the number of wells
for a positive control and a negative control in a plate to
obtain reasonably confident results when SSMD is used as a
QC metric. This question can be explored in theory, which
can become very complicated. In practice, we frequently have
the design of 32, 16, 8, or 4 wells in a 16-by-24 plate for
either a negative control or a positive control. The application
under Results suggests that 4 wells per plate for a control
seems not enough while 8 wells or more may be reasonable,
although the more replicates the better the performance of
SSMD.The second question to be faced is how to deal with the
situation in which the measured intensity is skewed and has
outliers since SSMD and CVD are based on normality
assumption. This is important because it is not unusual for
the measured raw intensity to have outliers and to be not
normally or even not symmetrically distributed. The first
strategy to deal with it is to use transformation to make the data
nearly normally (or at least nearly symmetrically) distributed.
The commonly used are log-transformation and square-root
transformation. The second strategy is to use both regular and
robust estimation of SSMD (or CVD) and double-check the
plates that are disagreed by the two types of estimates for
outliers.
The third question is how to choose the cutoff value of
SSMD for different experiments. In practics, some HTS assays
may have only strong positive (or negative) controls while
other assays may have only weak positive (or negative)
controls. Some assays may even have both strong and weak
positive controls in a plate, such as in the HCV RNAi HTS
assay [17]. The assay with good quality should have bigger
separation between strong positive controls and negative
controls than between weak positive controls and negative
controls. Thus, to evaluate assay quality, the QC cutoff
criterion using strong positive controls should be different
from the criterion using weak positive controls. For example,
in the situation where positive control should have value
bigger than negative controls, when using the strong positive
control, we may use the criterion of SSMD>6 to indicate good
quality while we may use the criterion of SSMD>3 when
using weak positive controls. In some situations, we may have
only very weak biological positive controls in a whole
experiment. In these situations, the criterion of SSMD>2 may
even be enough to indicate good quality.
We have investigated the use of SSMD or CVD as QC
metrics in RNAi HTS assays. SSMD and CVD are applicable
not only in various RNAi HTS assays targeting a variety of
diseases including infectious diseases, cancers, and complex
neurodiseases, but also in other HTS assays including small-
molecule HTS assays. SSMD and CVD measure the
magnitude of difference between two groups in general.
Hence, in addition to being used as QC metrics, they may
have other applications such as in hit selection in HTS
assays. In the future, more theoretical research on SSMD and
CVD can be also done. For example, the data from real
experiments seem to suggest that the sample size of 8 or
more is reasonably good, whereas a sample size of 4 is not
big enough for the use of SSMD for QC in RNAi HTS
assays. How can we determine the sample size requirement
theoretically? The probability meanings of SSMD and CVD
are based on the normality assumption; and the MLE
estimation and properties work best in normal distributions.
What will happen if the normality assumption is violated
even after applying commonly used transformation? How
could we adjust the SSMD or CVD estimation? In sum-
mary, SSMD and CVD have many other potential applica-
tions in HTS assays and more research can be conducted on
them.
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Appendix A
Proposition 1
If X11, X12,… , X1n1, are independently identically distributed (IID) from N (μ1, σ1
2), and X21, X22,… , X2n2 are IID from
N (μ2, σ2
2), and both samples are independent of each other, then the MLEs of SSMD and CVD are, respectively,
b ̂ ¼ X
¯
1  X¯2ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
n1  1
n1
s21 þ
n2  1
n2
s22
r ð12Þ
x̂¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
n1  1
n1
s21 þ
n2  1
n2
s22
r
X¯1  X¯2
; ð13Þ
where X¯k ¼ 1nk
Xnk
i¼1
Xki and sk ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1
nk1
Pnk
i¼1

Xki  X¯k
2s
(k =1, 2) and β̂ and ω̂ are asymptotically unbiased estimates and are
asymptotically normally distributed. That is, βˆ and ωˆ have the following properties:
• consistency (i.e., asymptotic unbiasedness),
b̂Y
P
b0 and x̂Y
P
x0 as n1 or n2Yl; ð14Þ
• asymptotic normality,
b̂Y
D
Nðb0; r ̂b;2Þ and x̂Y
D
Nðx0; r
̂x
2Þ as B1 and n2Yl; ð15Þ
where
r ̂b;
2¼
r21
n1
þ r
2
2
n2
r21 þ r22
þ
r41
n1
þ r
4
2
n2
2ðr21 þ r22Þ3

l1  l2
2
; r
̂x
2 ¼ 1
2ðr21 þ r22Þ
þ r
2
1 þ r22
ðl1  l2Þ2
 ! r21
n1
þ r
2
2
n2
ðl1  l2Þ2
:
Proof
Let X=(X11, X12,… , X1n1,… , X21, X22,… , X2n2), X1= (X11, X12,… , X1n1), X2= (X21, X22,… , X2n2), θ=(μ
1, σ1
2, μ2, σ2
2)T, δ=(μ1, β,
μ2, σ2
2)T, f1(X1i; δ) be the distribution of X1i and f2 (X2i; δ) be the distribution of X2i. As shown in many classical textbook, the
MLEs of μ1, μ2, σ1
2, and σ2
2 are respectively X¯1, X¯2,
n1  1
n1
s1
2, and
n2  1
n2
s2
2. By the invariance property of MLE, the MLE of
β is b ̂ ¼ X
¯
1  X¯2ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
n1  1
n1
s21 þ
n2  1
n2
s22
r . Thus, we have the MLE of β given in Eq. (12).
The log-likelihoods of X1, X2, and X are respectively
l1ðdÞ ¼
X
i¼1
n1i
log f1ðX1i; dÞ; l2ðdÞ ¼
Xn2i
i¼1
log f2ðX2i; dÞ; and lðdÞ ¼ l1ðdÞ þ l2ðdÞ:
Because l2 (δ) depends on the parameters of μ2 and σ2
2 only,
A
l2ðdÞ ¼ 0. δ̂ is the MLE of δ with respect to l(δ). Thus,Ab
A
Ab
l d ̂
 
¼ 0. Therefore, 0 ¼ A
Ab
l d ̂
 
¼ A
Ab
l1 d
̂
 
þ A
Ab
l2 d
̂
 
¼ A
Ab
l1 d
̂
 
. That is, the MLE of δ with respect to l(δ) is also the
560 X.D. Zhang / Genomics 89 (2007) 552–561MLE of δ with respect to l1(δ). Considering that (X11, X12, …, X1n1) is IID, by the consistency of MLE based on an IID sample, we
have b̂YP b0 as n1→∞.
Similarly, using δ1 = (μ1, σ1
2, μ2, β), we can prove that b
̂YP b0 as n2→∞.
Let h1 ¼

l1; r
2
1
T
and h ̂1 ¼ X¯1; n1  1n1 s
2
1
 T
. By the asymptotical normality and efficiency of MLE from the IID sample X1,
we have
ﬃﬃﬃﬃ
n1
p ðh ̂1  h1ÞY
D
Nð0; I1ðh1ÞÞ as n1Yl;
where
I h1ð Þ ¼ E  A
2
Ah21
log f1 X11; h1ð Þ
 !
:
It is trivial to show that
I h1ð Þ ¼ E  A
2
Ah21
log f1 X11; h1ð Þ
 !
¼
1
r21
0
0
1
2r41
0
BB@
1
CCA:
Therefore, as n1→∞,
ﬃﬃﬃﬃ
n1
p ðð X¯1n1  1
n1
s21Þð l1r21ÞÞYD Nðð 00Þ;ð r21 00 2r41ÞÞ:
Similarly, we can obtain that, as n2→∞,
ﬃﬃﬃﬃ
n2
p X¯2
n2  1
n2
s22
0
@
1
Að l2r220@ 1AÞYD Nðð 00Þ;ð r22 00 2r42ÞÞ:
Therefore, considering the two samples are independent, as n1 and n2→∞,
X¯
n1  1
n1
s21
X¯ 2
n2  1
n2
s22
0
BBBBB@
1
CCCCCA
l1
r21
l2
r22
0
BB@
1
CCA
0
BBBBB@
1
CCCCCAY
D
N
0
0
0
0
0
BB@
1
CCA;
r21
n1
0 0 0
0
2r41
n1
0 0
0 0
r22
n2
0
0 0 0
2r42
n2
0
BBBBBBBBBB@
1
CCCCCCCCCCA
0
BBBBBBBBBB@
1
CCCCCCCCCCA
:
By the Delta method (cf. [23]),
b̂  b0Y
D
N 0;
Ab
AhT
r21
n1
0 0 0
0
2r41
n1
0 0
0 0
r22
n2
0
0 0 0
2r42
n2
0
BBBBBBBBBB@
1
CCCCCCCCCCA
Ab
Ah
0
BBBBBBBBBB@
1
CCCCCCCCCCA
; ð16Þ
where
Ab
AhT
¼ Ab
Al1
;
Ab
Ar21
;
Ab
Al2
;
Ab
Ar22
0
BB@
1
CCA ¼ 1ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃr21 þ r22p ;
l1  l2
r21 þ r22
 3
2
 1ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
r21 þ r22
p ; l1  l2
r21 þ r22
 3
2
0
BB@
1
CCA:
561X.D. Zhang / Genomics 89 (2007) 552–561By plugging the above partial derivatives into Eq. (16), we obtain Eq. (15). Therefore, the two properties of the MLE of SSMD have
been proven.
Using an approach similar to the proof of the part related to SSMD in Proposition 1, we can prove the part of Proposition 1 related
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